Zusammenfassung
Der Lupus erythematodes (LE) ist eine entzündliche Autoimmunerkrankung, die sich durch eine große klinische Heterogenität und variable Verläufe auszeichnet. Beim systemischen Lupus erythematodes (SLE) besteht die Möglichkeit der Entwicklung einer lebensbedrohlichen Beteiligung multipler Organe, die Haut, Bewegungsapparat, Nieren, kardiovaskuläres und zentralnervöses System betreffen kann. Auch kann sich die Erkrankung nur auf die Haut beschränken und wird dann als kutaner Lupus erythematodes (CLE) bezeichnet. Vor einem (immun)genetischen Hintergrund führen verschiedene Umweltfaktoren, wie Rauchen, Medikamente, Hormone, Infektionen und vor allem die ultraviolette (UV) Strahlung, zu einer Erstmanifestation oder Exazerbation der Erkrankung. Neue Erkenntnisse zur Pathogenese des CLE haben auch zu weiteren therapeutischen Optionen dieser Autoimmunerkrankung geführt.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
Literatur
Albrecht J, Taylor L, Berlin JA et al (2005) The CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index): an outcome instrument for cutaneous lupus erythematosus. J Invest Dermatol 125:889–894
Baima B, Sticherling M (2001) Apoptosis in different cutaneous manifestations of lupus erythematosus. Br J Dermatol 144:958–966
Biazar C, Sigges J, Patsinakidis N et al (2013) Cutaneous lupus erythematosus: first multicenter database analysis of 1002 patients from the European Society of Cutaneous Lupus Erythematosus (EUSCLE). Autoimmun Rev 12:444–454
Cancro MP, D’Cruz DP, Khamashta MA (2009) The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus. J Clin Invest 19:1066–1073
Costner MI, Sontheimer RD, Provost TT (2003) Lupus erythematosus. In: Sontheimer RD, Provost TT (Hrsg) Cutaneous manifestations of rheumatic diseases. Williams & Wilkins, Philadelphia, S 15–64
Crowson AN, Magro C (2001) The cutaneous pathology of lupus erythematosus: a review. J Cutan Pathol 28:1–23
Dalle Vedove C, Simon JC, Girolomoni G (2012) Medikamenteninduzierter Lupus erythematodes unter besonderer Berücksichtigung von Hautmanifestationen und Anti-TNFα-Therapeutika. J Dtsch Dermatol Ges 10:889–897
Fischer-Betz R (2012) Rheumatische Erkrankungen in der Schwangerschaft. Internist (Berl) 53:1047–1053
Franceschini F, Cavazzana I (2005) Anti-Ro/SSA and La/SSB antibodies. Autoimmunity 38:55–63
Furie R, Petri M, Zamani O et al (2011) A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 63:3918–3930
Gilliam JN, Sontheimer RD (1981) Distinctive cutaneous subsets in the spectrum of lupus erythematosus. J Am Acad Dermatol 4:471–475
Jessop S, Whitelaw D, Jordaan F (2009) Drugs for discoid lupus erythematosus. Cochrane Database Syst Rev (4):CD002954
Kuhn A, Bonsmann G, Aberer E et al (2009) Leitlinien Kutaner Lupus Erythematosus (Entwicklungsstufe 1). In: Korting HC, Callies R, Reusch M, Schlaeger M, Sterry W (Hrsg) Dermatologische Qualitätssicherung: Leitlinien und Empfehlungen, Bd 6. ABW Wissenschaftsverlag, Berlin, S 214–257
Kuhn A, Amler S, Beissert S et al (2010) Revised Cutaneous Lupus Erythematosus Disease Area and Severity Index (RCLASI): a modified outcome instrument for cutaneous lupus erythematosus. Br J Dermatol 163:83–92
Kuhn A, Ruland V, Bonsmann G (2010) Photosensitivity, phototesting and photoprotection in cutaneous lupus erythematosus. Lupus 19:1036–1046
Kuhn A, Ruland V, Bonsmann G (2011) Hautmanifestationen des Lupus erythematodes. Z Rheumatol 70:213–227
Kuhn A, Ruland V, Bonsmann G (2012) Cutaneous lupus erythematosus: update of therapeutic options Part I, II. J Am Acad Dermatol 65:e179–e193, e195–e213
Kuhn A, Bonsmann G, Anders HJ et al (2015) Diagnose und Therapie des systemischen Lupus erythematodes. Dtsch Arztebl 112:423–432
Kuhn A, Landmann A, Patsinakidis N et al (2016) Fumaric acid ester treatment in cutaneous lupus erythematosus (CLE): a prospective, open-label, phase II pilot study. Lupus 25:1357–1364
Kuhn A, Landmann A, Bonsmann G (2016) The skin in autoimmune diseases: unmet needs. Autoimmun Rev 15:948–954
Kuhn A, Wenzel J, Bijl M (2016) Lupus erythematosus revisited. Semin Immunopathol 38:97–112
Lee-Kirsch MA, Gong M, Schulz H et al (2006) Familial chilblain lupus, a monogenic form of cutaneous lupus erythematosus, maps to chromosome 3p. Am J Hum Genet 79:731–737
Manzi S, Sanchez-Guerrero J, Merrill JT et al (2012) Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials. Ann Rheum Dis 71:1833–1838
Marmor MF, Kellner U, Lai TY et al (2016) Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 Revision). Ophthalmology 123:1386–1394
Massone C, Kodama K, Salmhofer W et al (2005) Lupus erythemtaosus panniculitis (lupus profundus): clinical, histopathological and molecular analysis of nine cases. J Cutan Pathol 32:396–404
Melles RB, Marmor MF (2014) The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy. JAMA Ophthalmol 132:1453–1460
Merrill JT, Neuwelt CM, Wallace DJ et al (2010) Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 62:222–233
Navarra SV, Guzman RM, Gallacher AE et al (2011) Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomized, placebo-controlled, phase 3 trial. Lancet 377:721–731
Ochsendorf FR (2010) Einsatz von Antimalariamitteln in der Dermatologie. J Dtsch Dermatol Ges 8:829–846
Petri M, Orbai AM, Alarcón GS et al (2012) Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 64:2677–2686
Renner R, Sticherling M (2008) Incidental cases of subacute cutaneous lupus erythematosus in association with malignancy. Eur J Dermatol 18:700–704
Renner R, Sticherling M (2009) The different faces of cutaneous lupus erythematosus. G Ital Dermatol Venereol 144:135–147
Risselada AP, Kallenberg CG (2006) Therapy-resistant lupus skin disease successfully treated with rituximab. Rheumatology 45:915–916
Rovin BH, Furie R, Latinis K et al (2012) Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum 64:1215–1226
Ruland V, Haust M, Stilling RM et al (2013) Updated analysis of standardized photoprovocation in patients with cutaneous lupus erythematosus. Arthritis Care Res (Hoboken) 65:767–776
Schmitt V, Meuth AM, Amler S et al (2010) Lupus erythematosus tumidus is a separate subtype of cutaneous lupus erythematosus. Br J Dermatol 162:64–73
Shinada S, Wallace DJ (2004) Laboratory features of cutaneous lupus erythematosus. In: Kuhn A, Lehmann P, Ruzicka T (Hrsg) Cutaneous Lupus Erythematosus. Springer, Berlin, S 301–322
Smith CD, Cyr M (1988) The history of lupus erythematosus. From Hippocrates to Osler. Rheum Dis Clin North Am 14:1–14
Sontheimer RD, Henderson CL, Grau RH (2009) Drug-induced subacute cutaneous lupus erythematosus: a paradigm for bedside-to-bench patient-oriented translational clinical investigation. Arch Dermatol Res 301:65–70
Tan EM, Cohen AS, Fries JF et al (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271–1277
Terrier B, Amoura Z, Ravaud P et al (2010) Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry. Arthritis Rheum 62:2458–2466
Toberer F, Sykora J, Göttel D et al (2013) Apoptotic signal molecules in skin biopsies of cutaneous lupus erythematosus: analysis using tissue microarray. Exp Dermatol 22:656–659
Uthman I, Taher A, Abbas O et al (2008) Successful treatment of refractory skin manifestations of systemic lupus erythematosus with rituximab: report of a case. Dermatology 216:257–259
Erstbeschreiber
Bechet PE (1942) Lupus erythematodes hypertrophicus et profundus. Arch Derm Syphilol 45:33–39
Brocq L (1921) Précis-atlas de pratigue dermatologique. Doin, Paris, S 468–477
Cazenave A, Schedel HE (1833) Abrégé pratique des maladies de la peau. 2ième ed. Béchet, Paris.
Cazenave PLA (1851) Lupus érythemateaux (érythéme centrifuge). Ann Mal Peau Syph 3:297–299
Gougerot H, Burnier R (1930) Lupus érythémateux tumidus. Bull Soc Fr Dermatol Syphiligr 37:1291–1292
Hebra F (1845) Versuch einer auf pathologische Anatomie gegründeten Einteilung der Hautkrankheiten. K. K. Ges Aerzte Wien 1:34–52, 141–155, 211–231
Hoffmann E (1909) Isolierter Lupus erythematodes tumidus der Gesichtshaut. Derm Z 16:159–160
Hutchinson J (1888) Harveian lectures on lupus. The varieties of common lupus. Br Med J 1:113–118
Irgang S (1940) Lupus erythematosus profundus: report of an example with clinical resemblance to Darier-Roussy sarcoid. Arch Derm Syphilol 42:97–108
Kaposi MH (1872) Neue Beiträge zur Kenntnis des Lupus erythematosus. Arch Dermatol Syphilol 4:36–78
Kaposi M (1883) Pathologie und Therapie der Hautkrankheiten in Vorlesungen für praktische Ärzte und Studierende, 2. Aufl. Urban & Schwarzenberg, Wien, S 642
McCustion CH, Schoch EP Jr (1954) Possible discoid lupus erythematosus in newborn infant; report of a case with subsequent development of acute systemic lupus erythematosus in mother. AMA Arch Derm Syphilol 70:782–785
O’Leary PA (1934) Disseminated lupus erythematosus. Minn Med 17:637–644
Pedro SD, Dahl MV (1973) Direct immunofluorescence of bullous systemic lupus erythematosus. Arch Dermatol 107:118–120
Rowell NR, Beck S, Anderson JR (1963) Lupus erythematosus and erythema multiforme-like lesions. Arch Dermatol 88:176–180
Scholtz M (1922) Lupus erythematosus acutus disseminatus hemorrhagicus. Arch Dermatol Syph 6:466475
Sontheimer RD, Thomas JR, Gilliam JN (1979) Subacute cutaneous lupus erythematosus: a cutaneous marker for a distinct lupus erythematosus subset. Arch Dermatol 115:1409–1415
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Section Editor information
Rights and permissions
Copyright information
© 2018 Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature
About this chapter
Cite this chapter
Sticherling, M., Kuhn, A. (2018). Lupus erythematodes. In: Plewig, G., Ruzicka, T., Kaufmann, R., Hertl, M. (eds) Braun-Falco’s Dermatologie, Venerologie und Allergologie. Springer Reference Medizin. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-49544-5_54
Download citation
DOI: https://doi.org/10.1007/978-3-662-49544-5_54
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-49543-8
Online ISBN: 978-3-662-49544-5
eBook Packages: Medicine (German Language)